Activity of pemetrexed in thoracic malignancies
|
|
- Neal Jenkins
- 8 years ago
- Views:
Transcription
1 Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is an antifolate agent with activity in many tumor types. Its mechanism of action involves inhibition of several enzymes involved in nucleotide synthesis principally thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase thereby inhibiting the replication of tumor cells. Initial experience with the agent showed that it produced rates of hematologic and non-hematologic toxicities similar to those of other antifolate compounds and antimetabolites. Subsequently, it was shown that these toxicities could be markedly reduced through routine folic acid and vitamin B 12 supplementation without adversely affecting the efficacy of the agent. 1 Pemetrexed has recently been evaluated in phase III trials in the settings of malignant pleural mesothelioma and non-small cell lung cancer (NSCLC). lowed 2 hours later by cisplatin (75 mg/m² via a 2-hour infusion) or cisplatin alone on day 1 every 21 days. Folic acid and vitamin B 12 supplementation was not instituted until after 117 patients had been enrolled. Thereafter, patients randomized to receive pemetrexed therapy received folic acid (350 1,000 µg orally) each day, beginning 1 3 weeks before the first dose of pemetrexed and continuing throughout the study therapy, and vitamin B 12 (1,000 µg intramuscularly) 1 3 weeks before starting treatment with pemetrexed and every 9 weeks during treatment. To prevent skin rash, patients treated with pemetrexed were also given dexamethasone on the day before, the day of, and the day after treatment. Patients in the cisplatin-alone group received a saline infusion, vitamin supplementation, and dexamethasone to maintain patient blinding. Baseline characteristics The pemetrexed/cisplatin and cisplatin-alone treatment groups were well matched with regard to baseline characteristics: Median age was Pemetrexed/cisplatin versus cisplatin alone in mesothelioma In the mesothelioma trial, 2 the combination of pemetrexed and cisplatin was compared with cisplatin alone in 456 patients with malignant pleural mesothelioma who were chemotherapy naïve and ineligible for curative surgery. Patients were randomized to receive pemetrexed (500 mg/m² via a 10-minute infusion) fol- Summary by Matt Stenger, MS; reviewed by Ben Solomon, MBBS, PhD, and Paul A. Bunn, Jr., MD, University of Colorado Cancer Center, Denver, CO. FIGURE 1 Kaplan-Meier estimates of overall survival among patients with malignant pleural mesothelioma treated with pemetrexed and cisplatin versus cisplatin alone. Reproduced from Vogelzang et al 2 with permission from the American Society of Clinical Oncology Elsevier Inc. All rights reserved. January/February 2005 COMMUNITY ONCOLOGY 21
2 Setting a new mesothelioma treatment standard Ben Solomon, MBBS, PhD, and Paul A. Bunn, Jr., MD University of Colorado Cancer Center, Denver NTIL RECENTLY, no proven systemic treatments existed for U patients with unresectable malignant pleural mesothelioma. The study by Vogelzang and colleagues described in this summary led in February 2004 to US Food and Drug Administration (FDA) approval of pemetrexed (Alimta) in combination with cisplatin for use in the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. This large, well-designed, randomized study represents the largest phase III study in mesothelioma reported to date. Patients randomized to the investigational pemetrexed/cisplatin treatment arm demonstrated a statistically significant improvement in clinical outcome, compared with those assigned to the cisplatin control arm, in terms of survival, time to disease progression, and response rate. Importantly, treatment with the pemetrexed/cisplatin combination was also found to result in improved pulmonary function and in improved patient-reported symptom scores and quality of life, compared with cisplatin-only treatment. Thus, this combination is the standard and only FDA-approved therapy for unresectable mesothelioma. Vitamin supplementation important The importance of folic acid and vitamin B 12 supplementation in patients treated with pemetrexed is highlighted in Vogelzang s study. Major toxicity, with three drug-related deaths, was seen in the first 43 patients (7%) recruited to the combination pemetrexed/cisplatin arm. Multivariate analyses of the outcomes of phase I and II studies in patients receiving pemetrexed demonstrated that deficiencies of folic acid and vitamin B 12 predicted an increased risk of various toxicities, including drugrelated death. 1 Elevated total plasma homocysteine (a marker of folic acid and also vitamin B 12 deficiency) levels were found to significantly predict severe thrombocytopenia, neutropenia, diarrhea, mucositis, and infection. Elevated methylmalonic levels (a specific marker of vitamin B 12 deficiency) predicted an increased risk of diarrhea and mucositis. These observations led to the recommendation that all patients treated with pemetrexed receive supplementation with a daily low oral dose of folic acid plus intramuscular injections of vitamin B 12 every 3 months. Folic acid and vitamin B 12 supplementation provided in this way not only reduces pemetrexed toxicity but also allows for the delivery of more cycles of pemetrexed chemotherapy and is associated with preserved or possibly increased efficacy. Reference 1. Niyikiza C, Hanauske AR, Rusthoven JJ, et al. Pemetrexed safety and dosing strategy. Semin Oncol 2002;29(suppl 18): Dr. Bunn (paul.bunn@uchsc.edu) is Grohne/ Stapp Professor and Director at the University of Colorado Cancer Center, Denver. Dr. Solomon (ben.solomon@uchsc.edu) is a fellow at the same institution. 61 years versus 60 years, respectively; 81.4% of the pemetrexed/cisplatin group were male versus 81.5% of the cisplatin-only group; 51.8% versus 56.3%, respectively, had a Karnofsky performance status of ; 68.1% versus 68.5% had an epithelial histology; and 7.1%, 15.6%, 32.4%, and 45.1% of patients receiving combination therapy versus 6.3%, 15.0%, 30.9%, and 48.2% of those receiving cisplatin alone had stage I, II, III, and IV disease, respectively. In all, 226 patients in the pemetrexed/cisplatin treatment group versus 222 in the cisplatin-alone group constituted the intent-to-treat population. Of this population, 168 versus 163 received full vitamin supplementation, 26 versus 21 received partial supplementation, and 32 versus 38 received no supplementation. Baseline characteristics among these subgroups were also similar. Efficacy Median survival was 12.1 months in the pemetrexed/cisplatin treatment group, significantly greater than the median survival of 9.3 months in the group that received cisplatin only (P = 0.020; Figure 1). The hazard ratio for death in the pemetrexed/cisplatin arm, compared with that in the cisplatin-only arm, was The difference in median survival did not quite reach significance among the patients receiving full vitamin supplementation (P = 0.051) but did so among all patients who received full or partial supplementation (P = 0.022). No difference between the subgroups who received no vitamin supplementation was observed, probably reflecting the small patient numbers in these two subgroups. Median time to disease progression was significantly longer (P < 0.01) in the pemetrexed/cisplatin treatment group among all patients, among those who received full vitamin supplementation, and among those with full or partial supplementation. The tumor response rate, assessed by se- 22 COMMUNITY ONCOLOGY January/February
3 rial computed tomographic scanning, was significantly greater (P < 0.001) in the pemetrexed/cisplatin treatment group, that is the group receiving cisplatin only, among all patients, among patients who had full vitamin supplementation, and among those with full or partial supplementation. All responses to chemotherapy were partial responses. Safety Compared with cisplatin therapy alone, pemetrexed/cisplatin treatment was associated with a significantly higher incidence of grade 3 or 4 hematologic and non-hematologic toxicities among all patients, including significantly more grade 3 or 4 nausea, vomiting, diarrhea, dehydration, and stomatitis (Table 1). Vitamin supplementation, however, reduced the frequency of adverse events. Patients who received pemetrexed/cisplatin therapy with full vitamin supplementation had significantly fewer occurrences of neutropenia or neutropenia with infection, as well as other grade 3/4 toxicities, compared with similarly treated patients who had partial or no vitamin supplementation (Table 2). Patients with full or partial vitamin supplementation had significantly reduced frequencies of leukopenia, nausea, vomiting, and febrile neutropenia, compared with patients receiving no supplementation. Conclusion These findings indicate a clear superiority of pemetrexed/cisplatin therapy over cisplatin alone in terms of survival time, time to disease progression, and objective response rates in patients with malignant pleural mesothelioma, although there is some cost in terms of increased toxicity. The findings also indicate, however, that the addition of folic acid and vitamin B 12 to pemetrexed therapy can markedly reduce toxicity without adversely affecting its efficacy. TABLE 1 Incidence (%) of grade 3/4 toxicities observed in mesothelioma patients receiving pemetrexed/cisplatin versus cisplatin alone Pemetrexed/cisplatin Cisplatin alone Toxicity (n = 226) (n = 222) Neutropenia Febrile neutropenia Neutropenia with infection Leukopenia Anemia Thrombocytopenia Nausea Vomiting Fatigue Diarrhea Dehydration Stomatitis Anorexia Rash Adapted from Vogelzang et al 2 with permission from the American Society of Clinical Oncology. TABLE 2 Incidence (%) of grade 3/4 toxicities observed in mesothelioma patients receiving pemetrexed/cisplatin with full or no vitamin supplementation Full supplementation No supplementation Toxicity (n = 168) (n = 32) Neutropenia Febrile neutropenia Neutropenia with infection Leukopenia Anemia Thrombocytopenia Nausea Vomiting Fatigue Diarrhea Dehydration Stomatitis Anorexia Rash Adapted from Vogelzang et al 2 with permission from the American Society of Clinical Oncology. January/February 2005 COMMUNITY ONCOLOGY 23
4 Pemetrexed versus docetaxel as secondline therapy for NSCLC In the lung cancer trial, patients who had received one prior chemotherapy regimen for advanced NSCLC and who had adequate organ function and an ECOG performance status of 0 2 were randomized to receive pemetrexed (500 mg/m² via a 10-minute infusion) or docetaxel (Taxotere; 75 mg/m² via a 1-hour infusion) on day 1 every 21 days. Patients receiving pemetrexed were instructed to take folic acid (350 1,000 µg orally) each day, beginning 1 2 weeks before the first dose of pemetrexed and continuing until 3 weeks after the last dose; in addition, a 1,000-µg vitamin B 12 injection was given intramuscularly 1 2 weeks before pemetrexed therapy was started and approximately every 9 weeks thereafter until study discontinuation. Dexamethasone (4 mg twice daily in the pemetrexed treatment group and 8 mg twice daily in the docetaxel treatment group) was administered the day before, the day of, and the day after study drug treatment to prevent skin rash. Baseline characteristics Both patient groups were well matched with regard to baseline characteristics: 68.6% of patients randomized to receive pemetrexed therapy versus 75.3% of those assigned to treatment with docetaxel were male; median age was 59 years versus 57 years, respectively; 88.6% versus 87.6% had an ECOG performance status of 0 or 1; 54.4% versus 49.3% had adenocarcinoma; 27.6% versus 32.3% had squamous cell cancer; 25.8% versus 27.8% had previously been treated with paclitaxel; and 44.2% versus 45.5% had received prior radiation therapy. Efficacy Objective response rates were 9.1% in the pemetrexed treatment FIGURE 2 Kaplan-Meier estimates of overall survival of patients given docetaxel versus pemetrexed as second-line therapy for non-small cell lung cancer. Reproduced from Hanna et al 3 with permission from the American Society of Clinical Oncology. arm and 8.8% in the docetaxel therapy arm, with stable disease occurring in 45.8% versus 46.4% of patients in both arms, respectively. Median disease progression-free survival was 2.9 months in each arm. Median survival was 8.3 months in the pemetrexed treatment arm versus 7.9 months in the docetaxel treatment arm, and the 1-year survival rate was 29.7% in each arm (Figure 2). The treatment groups did not differ significantly in any of these efficacy variables; however, a borderline significant improvement in median time to treatment failure was observed in the pemetrexed treatment group (2.3 months vs 2.1 months in the docetaxel group, P = 0.046). Safety Major differences in toxicity were observed between the two treatment arms (Table 3). Significantly more common in the docetaxel therapy arm were grade 3 or 4 neutropenia (40.2% vs 5.3%), febrile neutropenia (12.7% vs 1.9%), neutropenia with infection (3.3% vs 0.0%), hospitalizations for febrile neutropenia (13.4% vs 1.5%), use of colony-stimulating factor support (19.2% vs 2.6%), and alopecia (37.7% vs 6.4%). A grade 3 or 4 increase in serum alanine aminotransferase levels were observed in 1.9% of patients receiving pemetrexed, compared with none of the patients who received docetaxel. Conclusion These findings indicate that pemetrexed treatment is associated with equivalent efficacy and fewer adverse effects, compared with docetaxel, as second-line treatment of advanced NSCLC and suggest that pemetrexed should be considered a standard option in this setting. 24 COMMUNITY ONCOLOGY January/February
5 TABLE 3 Incidence (%) of grade 3/4 toxicities observed in patients receiving pemetrexed or docetaxel as second-line treatment of advanced NSCLC Pemetrexed Docetaxel Toxicity/resource utilization (n = 265) (n = 276) P value a Neutropenia < Febrile neutropenia < Neutropenia with infection Anemia Thrombocytopenia Hospitalizations and supportive care 1 Hospitalizations for < neutropenic fever Granulocyte or granulocyte < macrophage colony-stimulating factor support Erythropoietin support Red blood cell transfusion Alopecia b < Fatigue Nausea Elevation in serum ALT level a Fisher s exact test. b Any grade. ALT = alanine aminotranferase. Adapted from Hanna et al 3 with permission from the American Society of Clinical Oncology. References 1. Niyikiza C, Hanauske AR, Rusthoven JJ, et al. Pemetrexed safety and dosing strategy. Semin Oncol 2002;29(suppl 18): Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21: Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non smallcell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22: Pemetrexed: equivalent to docetaxel but less toxic Ben Solomon, MBBS, PhD, and Paul A. Bunn, Jr., MD University of Colorado Cancer Center, Denver HE PLACE OF DOCETAXEL (Taxotere) in the second-line treat- T ment of non-small cell lung cancer (NSCLC) has been firmly established by randomized studies in which docetaxel has been compared with best supportive care 1 or chemotherapy with vinorelbine or ifosfamide (Ifex). 2 The study of Hanna and colleagues described in this report utilized a non-inferiority statistical design to demonstrate the equivalence of pemetrexed (Alimta) with docetaxel in this setting. This multicenter study randomized 571 patients who had received one previous chemotherapy regimen to undergo treatment with either pemetrexed or docetaxel and represents the largest phase III study conducted to date in the second-line treatment of NSCLC. Treatment with pemetrexed resulted in efficacy equivalent to that of docetaxel, as measured by objective response rate, median disease progression-free survival, and median survival. Patientreported symptomatic improvement was largely equivalent in both treatment groups. However, treatment with pemetrexed, administered with concomitant folic acid and vitamin B 12 supplementation, was associated with less toxicity. Most significantly reduced rates of neutropenia and its related complications including febrile neutropenia and hospitalizations for neutropenic fever were seen in patients receiving pemetrexed. In addition, less alopecia was seen with pemetrexed than with docetaxel. This study establishes pemetrexed as a less-toxic alternative to docetaxel for the second-line treatment of patients with NSCLC and led to accelerated FDA approval of its use in this setting in July References 1. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol : Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non- Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18: January/February 2005 COMMUNITY ONCOLOGY 25
Prior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
More informationScottish Medicines Consortium
Scottish Medicines Consortium pemetrexed 500mg infusion (Alimta ) No. (192/05) Eli Lilly 8 July 2005 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS
More informationThird-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status
Available online at www.sciencedirect.com Journal of the Chinese Medical Association 74 (2011) 209e214 Original Article Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with
More informationAdvances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004
Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer
More informationMedication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010
Medication Policy Manual Policy No: dru213 Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Committee Approval Date: February 17, 2015 Next Review Date: February 2016 Effective Date: March 1, 2015
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Crizotinib as 2nd line treatment for patients with anaplastic lymphoma kinase (ALK) positive lung cancer Score The application
More informationBackground. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationSummary of treatment benefits
Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell
More informationIs the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study
Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,
More informationREPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory
More informationPemetrexed and Network Cancer in Singapore
Original Article Singapore Med J 2011; 52(3) : 190 Pemetrexed in the treatment of thoracic malignancies: a single centre experience in Singapore Lopes G, Chopra A, Kukutschka J, Portillo P, Bharwani L,
More informationPOLICY A. INDICATIONS
Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below
More informationNCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10
Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage
More informationMALIGNANT PLEURAL mesothelioma (MPM) is a locally
Phase III Study of Pemetrexed in Combination With Versus Alone in Patients With Malignant Pleural Mesothelioma By Nicholas J. Vogelzang, James J. Rusthoven, James Symanowski, Claude Denham, E. Kaukel,
More informationSecond-Line Treatment Options in Non Small Cell Lung Cancer: A Comparison of Cytotoxic Agents and Targeted Therapies
Second-Line Treatment Options in Non Small Cell Lung Cancer: A Comparison of Cytotoxic Agents and Targeted Therapies Filippo de Marinis, a Stefano De Santis, a and Luigi De Petris b Current options for
More informationConsiderations for Second-Line Therapy of Non-Small Cell Lung Cancer
Considerations for Second-Line Therapy of Non-Small Cell Lung Cancer Thomas E. Stinchcombe, Mark A. Socinski Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel
More informationWest of Scotland Cancer Network Chemotherapy Protocol. Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021)
West of Scotland Cancer Network Chemotherapy Protocol Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021) Indication Palliative chemotherapy for malignant mesothelioma of the pleura Eligibility
More informationPost-operative intrapleural chemotherapy for mesothelioma
Post-operative intrapleural chemotherapy for mesothelioma Robert Kratzke, MD John Skoglund Chair for Lung Cancer Research Section of Heme-Onc-Transplant University of Minnesota Medical School Efficacy
More informationJanuary 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationSummary ID# 13095. Clinical Study Summary: Study H3E-EW-B012
Page 1 Summary ID# 13095 Clinical Study Summary: Study H3E-EW-B012 First-line Treatment of Non-Small Cell Lung Cancer under Routine Conditions: Observational Study on Overall Survival Date summary electronically
More informationGemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
More informationLondon Cancer. Mesothelioma Lung Protocols
London Cancer Mesothelioma Lung Protocols Version 0.9 Contents 1. Staging... 3 2. Mesothelioma Summary of Chemotherapy Protocols... 4 3. Mesothelioma Chemotherapy Protocols... 7 3.1. Pemetrexed (Alimta
More informationSECOND-LINE CHEMOTHERAPY in advanced non
Gemcitabine as Second-Line Treatment for Advanced Non Small-Cell Lung Cancer: A Phase II Trial By Lucio Crinò, Anna Maria Mosconi, Giorgio Scagliotti, Giovanni Selvaggi, Silvia Novello, Massimo Rinaldi,
More informationEmerging Drug List GEFITINIB
Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:
More informationOut-Patient Chemotherapy for Lung Cancer
Lung Cancer Out-Patient Chemotherapy for Lung Cancer Principles and practice JMAJ 46(12): 542 546, 2003 Shuichi YONEDA Director, Department of Pulmonary Medicine, Saitama Cancer Center Abstract: Recent
More informationNew Treatment Options for Breast Cancer
New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of
More informationCancer Treatment Reviews
Cancer Treatment Reviews 35 (2009) 364 373 Contents lists available at ScienceDirect Cancer Treatment Reviews journal homepage: www.elsevierhealth.com/journals/ctrv ANTI-TUMOUR TREATMENT Pemetrexed in
More informationChapter 7: Lung Cancer
Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin
More informationDrug Review Pemetrexed for Injection Alimta
Drug Review Pemetrexed for Injection Alimta Reviewer: Jamilah Al-Saedan B.Sc Pharm, King Saud University Introduction Malignant pleural mesothelioma A rare form of cancer. It is a malignant tumor of the
More informationCheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early
April 21, 2015 CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early Opdivo Demonstrates Superior Overall Survival Compared to Docetaxel in Patients with Previously-Treated
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationHow valuable is a cancer therapy? It depends on who you ask.
How valuable is a cancer therapy? It depends on who you ask. Comparing and contrasting the ESMO Magnitude of Clinical Benefit Scale with the ASCO Value Framework in Cancer Ram Subramanian Kevin Schorr
More informationCancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
More informationReport on New Patented Drugs - Alimta
Report on New Patented Drugs - Alimta Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB s Excessive
More informationClinical Study Report
An Open, Multi-Center, Phase II Clinical Trial to Evaluate Efficacy and Safety of Taxol (), UFT, and Leucovorin in Patients with Advanced Gastric Cancer Clinical Study Report 4F, No. 156, Jiankang Rd.,
More informationPage 1 of 6 Origination Date: 08/13 Revision Date(s): 12/13, 12/14, 04/2015 Developed By: Medical Criteria Committee Effective Date: 10/1/2013
Moda Health Plan, Inc. Medical Necessity Criteria Subject: Alimta (pemetrexed) Page 1 of 6 Origination Date: 08/13 Revision Date(s): 12/13, 12/14, 04/2015 Developed By: Medical Criteria Committee Effective
More informationTHE RESULTS OF A large meta-analysis of 52 randomized
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy By Frances A. Shepherd, Janet Dancey,
More informationIMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Investigators: Paul G. Shekelle, MD, PhD, Director Alicia R. Maher, MD Clinical
More informationINITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been
More informationDOXETAXEL IN PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER PATIENTS: CLINICAL EFFICACY AND QUALITY OF LIFE
SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH DOXETAXEL IN PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER PATIENTS: CLINICAL EFFICACY AND QUALITY OF LIFE Thitiya Sirisinha 1, Suwanee Sirilertrakul 2, Manmana
More informationIntroduction Objective Methods Results Conclusion
Introduction Objective Methods Results Conclusion 2 Malignant pleural mesothelioma (MPM) is the most common form of mesothelioma a rare cancer associated with long latency period (i.e. 20 to 40 years),
More informationPrincipal Investigator: Valerie W. Rusch, MD, FACS, Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center
Protocol 1101-1088 Phase I study of intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion: primary, metastases and mesothelioma Principal Investigator: Valerie W. Rusch, MD,
More informationDrug/Drug Combination: Bevacizumab in combination with chemotherapy
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy
More informationPRODUCT MONOGRAPH ALIMTA
PRODUCT MONOGRAPH Pr ALIMTA Pemetrexed Disodium for Injection 100 mg or 500 mg pemetrexed per vial Antineoplastic Agent Eli Lilly Canada Inc. 3650 Danforth Avenue Toronto, Ontario M1N 2E8 1-888-545-5972
More informationLung Pathway Group Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC)
Indication: NICE TA181 First line treatment option in advanced or metastatic non-squamous NSCLC (histology confirmed as adenocarcinoma or large cell carcinoma) Performance status 0-1 Regimen details: Pemetrexed
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
More informationRedacted Protocol for Journal of Clinical Oncology
Redacted PARAMOUNT Clinical Protocol Page 1 Redacted Protocol for Journal of Clinical Oncology Protocol S124(b) (PARAMOUNT) A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance plus Best Supportive
More informationStage I, II Non Small Cell Lung Cancer
Stage I, II Non Small Cell Lung Cancer Best Results T1 (less 3 cm) N0 80% 5 year survival No Role Adjuvant Chemotherapy Radiation Therapy Reduces Local Recurrence No Improvement in Survival 1 Staging Mediastinal
More informationPreliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors
Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors John Goldberg 1 *, George Demetri 2, Edwin Choy 3, Lee Rosen 4, Alberto
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationShifting the Paradigm for Maintenance Therapy for Non small-cell Lung Cancer
J Hong Kong Col Radiol. 2010;13(Suppl):S16-21 ORIGINAL ARTICLE Shifting the Paradigm for Maintenance Therapy for Non small-cell Lung Cancer VHF Lee Department of Clinical Oncology, Queen Mary Hospital,
More informationAttached from the following page is the press release made by BMS for your information.
July 22, 2015 CheckMate -025 (global clinical trial), a Pivotal Phase III Opdivo (nivolumab) Renal Cancer Trial Stopped Early (PRINCETON, NJ, July 20, 2015) Bristol-Myers Squibb Company (NYSE:BMY) announced
More informationEverolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More informationAdjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
More informationAvastin in Metastatic Breast Cancer
Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche
More informationAnti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate
+ Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN
More informationLow dose capecitabine is effective and relatively nontoxic in breast cancer treatment.
1 Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment. John T. Carpenter, M.D. University of Alabama at Birmingham NP 2508 1720 Second Avenue South Birmingham, AL 35294-3300
More informationPemetrexed in Malignant Pleural Mesothelioma
982 Vol. 11, 982 992, February 1, 2005 Clinical Cancer Research Report from the Food and Drug Administration Pemetrexed in Malignant Pleural Mesothelioma Maitreyee Hazarika, Robert M. White, Jr., Brian
More informationLung Cancer and Mesothelioma
Lung Cancer and Mesothelioma Robert Kratzke, M.D. John C. Skoglund Professor of Lung Cancer Research Section of Heme/Onc/Transplant Department of Medicine University of Minnesota Medical School Malignant
More informationActive centers: 2. Number of patients/subjects: Planned: 20 Randomized: Treated: 20 Evaluated: Efficacy: 13 Safety: 20
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationManagement of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist
Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the
More informationManagement of Platinum-Sensitive Recurrent Ovarian Cancer
Management of Platinum-Sensitive Jacobus Pfisterer a and Jonathan A. Ledermann b The majority of patients with ovarian cancer will relapse despite state-of-the-art first-line surgery and chemotherapy.
More informationBrigham and Women s Hospital, Boston, MA, USA; 2 Verastem, Inc., Boston, MA, USA
Determination of Biomarker Response in a Phase II Window of Opportunity Study of Defactinib (VS 6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Resectable Malignant Pleural Mesothelioma
More informationSchedule: Drug Dose iv/infusion/oral q Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8
Carboplatin/Gemcitabine Lung Cancer (non-small cell) - Advanced Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8 Cycle frequency: Every three weeks Total
More informationCLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15
Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationClinical Trial Endpoints for the Approval of Non- Small Cell Lung Cancer Drugs and Biologics Guidance for Industry
Clinical Trial Endpoints for the Approval of Non- Small Cell Lung Cancer Drugs and Biologics Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
More informationLenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)
Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade
More informationRole of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly
More informationBCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP)
BCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP) Protocol Code Tumour Group Contact Physician UGUTIP Genitourinary Dr.
More informationSecond-Line Chemotherapy for Non-Small-Cell Lung Cancer
Chapter Second-Line Chemotherapy for Non-Small-Cell Lung Cancer 24 Eleni Karapanagiotou and Konstantinos N. Syrigos Contents 24.1 Background... 305 24.2 Docetaxel... 305 24.3 Pemetrexed... 307 24.4 Other
More informationStrength of Study End Point(s): Progression-free survival
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Paclitaxel for the First-line Treatment of Metastatic Breast Cancer Drug/Drug Combination: Bevacizumab and
More informationMesothelioma. Information for Patients and Families. identifying and evaluating experimental
Mesothelioma CLINICAL TRIALS Information for Patients and Families identifying and evaluating experimental treatments table of contents Pg. 2... Phases of a Clinical Trial Pg. 3... Mesothelioma and Clinical
More informationBefore, Frank's immune cells could
Before, Frank's immune cells could barely recognize a prostate cancer cell. Now, they are focused on it. Stimulate an immune response against advanced prostate cancer Extend median survival beyond 2 years
More informationGuidance for Industry
Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
More informationMALIGNANT MESOTHELIOMA is an aggressive
Cisplatin and Gemcitabine Treatment for Malignant Mesothelioma: A Phase II Study By M.J. Byrne, J.A. Davidson, A.W. Musk, J. Dewar, G. van Hazel, M. Buck, N.H. de Klerk, and B.W.S. Robinson Purpose: We
More informationAdvancing Personalized Therapy for Advanced Non-Small Cell Lung Cancer
GUIDING THE WAY White Paper Advancing Personalized Therapy for Advanced Non-Small Cell Lung Cancer is a serum proteomic test for patients with advanced non-small cell lung cancer that helps healthcare
More informationNon-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin
COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Docetaxel INDICATION: Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide
More informationClinical Trials for Patients with
Clinical Trials for Patients with Malignant Pleural Mesothelioma Lee M. Krug, M.D. Memorial Sloan-Kettering Cancer Center New York, New York Challenges in MPM Clinical Trials Mesothelioma is a rare disease,
More informationL Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
More informationLONDON CANCER NEWS DRUGS GROUP RAPID REVIEW. FOLFIRINOX for first line treatment of advanced pancreatic cancer January 2012
Background LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW FOLFIRINOX for first line treatment of advanced pancreatic cancer January 2012 The incidence of pancreatic cancer in the UK is 9.4/100,000. It is
More informationKasr El-Aini Center of Clinical Oncology, Faculty of medicine, 2 Chest Department, Faculty of medicine, Cairo University, egypt
Kasr El-aini J. Clin. Oncol. nucl. med. vol., no. 3-4, Jul.-oct. 006:4-47 NEMROCK Original Article Phase II Trial of Cisplatin and Vinorelbine as First-line Therapy in Malignant Pleural Mesothelioma Salah
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer September 3, 2015
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer September 3, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationFuture Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
More informationJ Clin Oncol 26:3567-3572. 2008 by American Society of Clinical Oncology INTRODUCTION
VOLUME 26 NUMBER 21 JULY 20 2008 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Pemetrexed Plus Gemcitabine As First-Line Chemotherapy for Patients With Peritoneal Mesothelioma: Final Report
More informationOvarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development
Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from
More informationEVALUATION/PRIORITIZATION CRITERIA: C, L, R, S *to meet requirement 1
COMPENDIA TRANSPARENCY TRACKING FORM DATE: MAY 2015 PACKET: 111 DRUG: INDICATION: Vinorelbine Tartrate Malignant pleural mesothelioma COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide criteria used to evaluate/prioritize
More informationTaxotere: Clinical Trials in Non-Small Cell Lung Cancer -- Ornstein and Rigas 3 (2): 86...
Page 1 of 11 HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH SEARCH RESULT The Oncologist, Vol. 3, No. 2, 86-93, April 1998 1998 AlphaMed Press This Article Taxotere: Clinical Trials in Non-Small Cell
More informationthe standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009
Mesothelioma: The standard of care Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009 take home messages PILC 2006 All patients should receive adequate palliation of dyspnea and pain before starting chemotherapy
More informationChemotherapy for non-small cell lung cancer
Chemotherapy for non-small cell lung cancer This information is an extract from the booklet Understanding lung cancer. You may find the full booklet helpful. We can send you a free copy see page 3. Contents
More informationLung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC) Indication: In combination with docetaxel in locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma
More informationSecond-Line Therapy in Non Small-Cell Lung Cancer: The DELTA Between Different Genotypes Widens
VOLUME 32 NUMBER 18 JUNE 20 2014 JOURNAL OF CLINICAL ONCOLOGY ONCOLOGY GRAND ROUNDS Second-Line Therapy in Non Small-Cell Lung Cancer: The DELTA Between Different Genotypes Widens Alona Zer and Natasha
More informationClinical Spotlight in Breast Cancer
2015 European Oncology Congress in Vienna Clinical Spotlight in Breast Cancer Reference Slide Deck Abstract #1815 Impact of Palbociclib Plus Fulvestrant on Global QOL, Functioning, and Symptoms Compared
More informationNATIONAL CANCER DRUG FUND PRIORITISATION SCORES
NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated
More informationPARP Inhibitors in Lung Cancer. Primo N. Lara, Jr., MD Professor of Medicine UC Davis Comprehensive Cancer Center
PARP Inhibitors in Lung Cancer Primo N. Lara, Jr., MD Professor of Medicine UC Davis Comprehensive Cancer Center Poly (ADP-ribose) Polymerase (PARP): Mechanism of Action PARPs: family of enzymes that repair
More informationTargeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany
Targeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany This presentation was selected by the 15 th World Conference on Lung Cancer Program Committee
More informationBREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I
BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I Overview Why is it important to understand breast cancer? Choosing wisely Appropriateness
More information